GLP-1 Receptor Agonists and Cardiovascular and Kidney Outcomes by Body Mass Index in Type 2 Diabetes - PubMed
3 hours ago
- #Cardiovascular outcomes
- #GLP-1 receptor agonists
- #Type 2 diabetes
- GLP-1 receptor agonists (GLP-1 RAs) reduce cardiovascular events in type 2 diabetes (T2DM) across diverse populations, with no significant heterogeneity by BMI.
- Individuals with overweight or obesity may experience greater absolute cardiovascular risk reduction due to improvements in visceral adiposity, inflammation, and insulin resistance.
- Renal benefits, such as slower decline in kidney function and reduced albuminuria, are uniform across BMI categories, reflecting mechanisms like natriuresis and reduced oxidative stress.
- GLP-1 RAs provide cardiorenal protection across the BMI spectrum, with cardiovascular benefits potentially accentuated in higher BMI individuals, while renal benefits remain consistent.
- The findings support broad use of GLP-1 RAs for cardiorenal risk reduction and suggest incorporating body-composition metrics beyond BMI in future treatment algorithms.